drugset / Trial / NCT04338360

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04338360

Expanded access Approved for marketing Mayo Clinic

Summary

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Timeline

Start
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic Other

Indications